Search results for " nano into micro strategy"

showing 2 items of 2 documents

Inhalable nano into micro dry powders for ivacaftor delivery: The role of mannitol and cysteamine as mucus-active agents.

2020

In this paper the innovative approach of Nano into micro (NiM9 was developed to produce Nanoparticles loaded Ivacaftor to incorporate into mannitol or mannitol/cysteamine micromatrices for drug pulmonary administration in CF. Nanoparticles composed by a mixture of two polyhydrohydroxyethtylaspartamide copolymers containing a loading of Ivacaftor of 15.5 % w/w were produced. These Nanoparticles were incorporated into microparticles to obtain NiM that were characterized in terms of size and size distribution, interaction with CF-AM by rheological and turbidimetric studies as well as by aerodynamic diameter measurements. Finally the activity of Ivacaftor into these NiM was evaluated by in vitr…

Cystic Fibrosisαβ-poly-(N-2-hydroxyethyl)-DL-aspartamide (PHEA) copolymer PHEA ivacaftor mucus-penetrating nanoparticle cell penetrating peptide nano into micro strategy. CysteamineDrug CompoundingPharmaceutical ScienceNanoparticleCystic Fibrosis Transmembrane Conductance Regulator02 engineering and technologyQuinolonesAminophenols030226 pharmacology & pharmacyIvacaftor03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNano-Administration InhalationMucus-penetrating nanoparticlemedicineCopolymerAnimalsMannitolChloride Channel AgonistsCells CulturedExpectorantsCell penetrating peptideNano into micro strategyChemistry021001 nanoscience & nanotechnologyMucusRats Inbred F344IvacaftorCopolymer PHEADrug LiberationSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoMutationNanoparticlesCysteamineMannitolPowders0210 nano-technologyPeptidesαβ-poly-(N-2-hydroxyethyl)-DL-aspartamide (PHEA)medicine.drugNuclear chemistryInternational journal of pharmaceutics
researchProduct

Nano into Micro Formulations of Tobramycin for the Treatment of Pseudomonas aeruginosa Infections in Cystic Fibrosis.

2017

Here, nano into micro formulations (NiMs) of tobramycin for the treatment of Pseudomonas aeruginosa airway infections in cystic fibrosis (CF) are described. NiMs were produced by spray drying a solution containing polymers or sugars and a nanometric polyanion–tobramcyin complex (PTC), able to achieve a prolonged antibiotic release. NiMs properties were compared to TOBIPodhaler(Novartis), the only one commercially available dry powder inhalatory formulation based on porous microparticles. Produced NiMs showed adequate characteristics for pulmonary administration, as spherical shape, micrometric size, and high cytocompatibility toward human bronchial epithelial cells. Contrarily to TOBIPodhal…

Tobramycin Cystic Fibrosis Artificial Mucus (CF-AM) αβ-poly-(N-2-hydroxyethyl)-DL-aspartamide (PHEA) ion pair complex nano into micro strategy Pseudomonas aeruginosa infections biofilmPolymers and PlasticsCystic FibrosisPolymersChemistry PharmaceuticalBioengineeringBronchi02 engineering and technologymedicine.disease_causeCystic fibrosisMicrobiologyBiomaterials03 medical and health sciences0302 clinical medicineDrug Delivery SystemsNano-Materials ChemistrymedicineTobramycinHumansPseudomonas InfectionsParticle SizeRespiratory Tract InfectionsCells CulturedDrug CarriersPseudomonas aeruginosaChemistryBiofilmDry Powder InhalersEpithelial Cells021001 nanoscience & nanotechnologyAntimicrobialmedicine.diseaseMucusPolyelectrolytesAnti-Bacterial Agents030228 respiratory systemSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoSpray dryingBiofilmsDelayed-Action PreparationsPseudomonas aeruginosaTobramycinNanoparticles0210 nano-technologymedicine.drugBiomacromolecules
researchProduct